However, under the therapeutic point of view, in terms of potential implication of basophils and/or IgE production in the pathophysiological process of SLE, the most interesting clinical application is the recent trial of omalizumab (anti-IgE monoclonal antibody) in patients with SLE. The gene discussed is IGHE; the disease is systemic lupus erythematosus.